Stay updated on Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial page.

Latest updates to the Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFooter now displays Revision: v3.6.6 on the Record History page, replacing the previous v3.6.5. This appears to be an update to the site version rather than a change to the trial data or visible content.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedVersion 63 introduces labeled sections for Eligibility, Study Status, and Study Identification in the Record History, organizing past changes by study-area for easier navigation.SummaryDifference0.3%

- Check47 days agoChange DetectedA new revision tag v3.6.4 was added to the page history, replacing the previous v3.6.3. This reflects a minor site update to the history page.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page revision label changed from v3.6.2 to v3.6.3, indicating a version update of the page. This update appears in the footer and does not affect the study data or visible content.SummaryDifference0.0%

- Check76 days agoChange DetectedA new revision entry (v3.6.2) was added to the study history on 2026-06-23, along with an added 'Study Status' item on 2026-05-28 and the version count updated to 62; the older revision (v3.6.0) was removed on 2026-04-09.SummaryDifference0.2%

- Check90 days agoChange DetectedRecruitment status is updated to show the study is no longer seeking participants. The history also adds a new revision tag (v3.6.0) and removes the older revision (v3.5.5).SummaryDifference0.2%

Stay in the know with updates to Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial page.